文献速递淋巴瘤

原发性纵隔大B细胞淋巴瘤中的体细胞IRF4突变与胸腺趋向性

Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma.
PubMed 文献 · Blood · 2025-01-01

研究通过大规模数据集突变荟萃分析发现IRF4-C99R突变独特存在于原发性纵隔大B细胞淋巴瘤(PMBCL),整合多组学与基因组编辑揭示该突变导致分化阻滞、降低PRDM1表达、抑制IFN-γ信号并增加TARC表达,且通过上调EPHB1促进胸腺定位,单核RNA测序在原发PMBCL组织中验证了上述体外机制。

要点

  • IRF4-C99R突变通过突变荟萃分析发现独特存在于PMBCL。
  • IRF4-C99R降低与PRDM1内ISRE基序结合,减少PRDM1表达导致分化阻滞。
  • IRF4-C99R上调EPHB1促进胸腺定位,不影响总体肿瘤负荷。

核心结论

  • 单个遗传突变IRF4-C99R协调调控PMBCL的标志性特征包括胸腺特异性趋向性。

研究设计与样本

  • 对大规模数据集进行突变荟萃分析,整合多组学方法与PMBCL细胞基因组编辑,并在免疫健全同基因淋巴瘤模型中过表达EPHB1,用单核RNA测序在原发PMBCL组织中验证。

主要发现

  • IRF4-C99R减少与PRDM1内ISRE基序结合,导致PRDM1表达降低。
  • IRF4-C99R通过损害ISRE基序结合抑制Traf2和Nck相互作用激酶,减少IFN-γ信号并增加TARC表达,驱动TARC介导的调节性T细胞趋化。
  • IRF4-C99R通过非经典激活蛋白1-IRF复合基序结合上调EPHB1,EPHB1过表达影响器官趋向性偏向胸腺定位,不影响总体肿瘤负荷。
  • 单核RNA测序在原发PMBCL组织中验证IRF4-C99R突变诱导的表型,确认体外观察的分子机制与患者病理生理一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disease-defining signatures in lymphomas, driven by intricate molecular mechanisms, have advanced molecular taxonomies, refined classification, and may guide clinical management; however, the role of these signatures in driving disease hallmarks, including subtype-specific organotropism, remains largely unexplored. Primary mediastinal large B-cell lymphoma (PMBCL) is an exemplary lymphoma characterized by disease manifestations in the thymic niche, unique genetic alterations, and immune escape. Here, we identified interferon regulatory factor 4 (IRF4)-C99R mutations uniquely occurring in PMBCL through mutational meta-analysis of large-scale data sets. By integrating multiomics approaches with genome editing in PMBCL cells, we revealed that IRF4-C99R contributes to a differentiation block phenotype. Specifically, we showed that IRF4-C99R reduces its binding to the interferon-stimulated response element (ISRE) motif within PRDM1, encoding a key transcriptional regulator of B-cell differentiation, resulting in decreased PRDM1 expression. Additionally, IRF4-C99R suppresses Traf2 and Nck-interacting kinase, a key interferon gamma (IFN-γ) pathway regulator, by impairing ISRE motif binding, thereby reducing IFN-γ signaling and increasing thymus and activation-regulated chemokine (TARC) expression, which drives TARC-mediated chemotaxis of T regulatory cells. We also revealed that IRF4-C99R upregulates ephrin type-B receptor 1 (EPHB1) through noncanonical activating protein 1-IRF composite motif binding and showed that overexpression of EPHB1 in an immunocompetent syngeneic lymphoma model influenced organotropism to favor thymic localization, without affecting overall tumor burden. IRF4-C99R mutation-induced phenotypes were validated in primary PMBCL tissues using single-nuclei RNA sequencing, confirming that the molecular mechanisms observed in vitro align with the pathophysiology of PMBCL in patients. Together, these findings demonstrate how a single genetic mutation orchestrates the coordinated regulation of hallmark traits including thymus-specific tropism in PMBCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rai S, Duns G, Frontzek F, et al. Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma. Blood. 2025. PMID: 40540746. doi:10.1182/blood.2025028412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。